MCMBP and pancreatic adenocarcinoma: In summary, our integrated analysis indicates that the low DNA methylation of MCMBP and its associated pro-tumorigenic m6A regulator profile may collectively constitute an epigenetic signature linked to adverse prognosis in PAAD.